Founded in 2011, Xique Pharma is a clinical-stage "global new" drug R&D company concentrating on the cardiovascular/cerebrovascular system and neurodegenerative diseases. According to the company website, it is developing multiple innovative drug candidates across these therapeutic areas. The candidate 硝酮嗪 is in Phase II clinical trials for ischemic stroke and diabetic nephropathy. MN-08 is in Phase I clinical studies for pulmonary arterial hypertension. The company has ongoing clinical and preclinical programs it plans to advance using the newly raised funds. No revenue or user metrics were reported in the article.

Total raised

$14M

Funding rounds

1

Latest round

Series C

Latest activity

Apr 2020